SEC Form 4 · accession 0000880771-17-000130
SCICLONE PHARMACEUTICALS INC · SCLN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Hong Zhao
Officer — CEO, China Operations
Period of report
Aug 15, 2017
Accepted (ET)
Aug 16, 2017 · 8:07 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000880771
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 15, 2017 | M | 30,000 | $0.00 | A | 30,000 | D | |
| Common Stock | Aug 16, 2017 | S | 30,000 | $11.00 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitF1,F2,F3 | — | Aug 15, 2017 | M | 30,000 | D | — | — | Common Stock | 30,000 | 127,000 | D |
Explanation of responses
- F1Granted under the Issuer's 2015 Equity Incentive Plan.
- F2Each restricted stock unit represents the right to receive, at settlement, one share of common stock.
- F3Each RSU will vest and be settled on August 15, 2017, subject to the reporting person's continued employment, but will terminate upon the occurrence of a change in control on or before March 31, 2017.